Filtered By:
Therapy: Cancer Therapy
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 13617 results found since Jan 2013.
Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report
Explor Res Clin Soc Pharm. 2023 Aug 24;11:100324. doi: 10.1016/j.rcsop.2023.100324. eCollection 2023 Sep.ABSTRACTThis case report describes the pharmacist intervention with a 62-year-old woman who had postmenopausal breast cancer. The patient was experiencing severe vasomotor symptoms from her cancer therapy and wanted to discontinue her treatment despite her risk of cancer returning. Using guidelines for treatment of postmenopausal breast cancer and medication options to mitigate vasomotor symptoms, the pharmacist developed a treatment plan that was acceptable to the patient and approved by the oncologist. Following imple...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Megan R Undeberg Alanda Barash Kimberly C McKeirnan Source Type: research
Green synthesis of chitosan/silver nanocomposite using kaempferol for triple negative breast cancer therapy and antibacterial activity
Environ Res. 2023 Sep 9:117109. doi: 10.1016/j.envres.2023.117109. Online ahead of print.ABSTRACTThe synthesis of polymer-encapsulated metal nanoparticles is a growing field of area due to their long-term uses in the development of new technologies. The present study describes the synthesis of chitosan/silver nanocomposite using kaempferol for anticancer and bactericidal activity. The formation of Kf-CS/Ag nanocomposite was confirmed by the development of a brown color and UV-absorbance around 438 nm. The IR study was utilized to determine the existence of Kf and CS in the synthesized nanocomposite. TEM analysis demonstrat...
Source: Environmental Research - September 11, 2023 Category: Environmental Health Authors: Devaraj Bharathi Rajamani Ranjithkumar Jaya Ganesh Thiruvengadam Nandagopal Sinouvassane Djearamane Jintae Lee Ling Shing Wong Source Type: research
Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report
Explor Res Clin Soc Pharm. 2023 Aug 24;11:100324. doi: 10.1016/j.rcsop.2023.100324. eCollection 2023 Sep.ABSTRACTThis case report describes the pharmacist intervention with a 62-year-old woman who had postmenopausal breast cancer. The patient was experiencing severe vasomotor symptoms from her cancer therapy and wanted to discontinue her treatment despite her risk of cancer returning. Using guidelines for treatment of postmenopausal breast cancer and medication options to mitigate vasomotor symptoms, the pharmacist developed a treatment plan that was acceptable to the patient and approved by the oncologist. Following imple...
Source: Clinical Breast Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Megan R Undeberg Alanda Barash Kimberly C McKeirnan Source Type: research
Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression
CONCLUSION: In conclusion, in vitro and in silico investigations show that the RMV extract improves the anticancer efficiency of SOR through molecular processes involving the downregulation of mTOR, BCl2, and JNK1 and overexpression of p21 tumor suppressor gene. Finally, we suggest conducting additional in vivo investigations on RMV and its bioactive components to verify their potential in cancer therapy.PMID:37696244 | DOI:10.1016/j.prp.2023.154807
Source: Pathology, Research and Practice - September 11, 2023 Category: Pathology Authors: Aml Ghanem Mohamed A Ali Mohamed A Elkady Sherif S Abdel Mageed Mahmoud A El Hassab Mohamed K El-Ashrey Osama A Mohammed Ahmed S Doghish Source Type: research
N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications
Biomed Pharmacother. 2023 Sep 9;167:115477. doi: 10.1016/j.biopha.2023.115477. Online ahead of print.ABSTRACTCancer therapy resistance (CTR) is the development of cancer resistance to multiple therapeutic strategies, which severely affects clinical response and leads to cancer progression, recurrence, and metastasis. N6-methyladenosine (m6A) has been identified as the most common, abundant, and conserved internal transcriptional alterations of RNA modifications, regulating RNA splicing, translation, stabilization, degradation, and gene expression, and is involved in the development and progression of a variety of diseases,...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 11, 2023 Category: Drugs & Pharmacology Authors: Dong Wang Yan Zhang Qingbo Li Ao Zhang Jingxuan Xu Yu Li Wen Li Lin Tang Fan Yang Jingyan Meng Source Type: research
Ribosomal RNA gene downregulation in head and neck squamous carcinoma cells correlates with rDNA promoter hypermethylation
Gene. 2023 Sep 9:147793. doi: 10.1016/j.gene.2023.147793. Online ahead of print.ABSTRACTEukaryotes carry hundreds of ribosomal RNA (rRNA) genes as tandem arrays, which generate rRNA for protein synthesis. Humans carry ∼ 400 rRNA gene copies and their expression is epigenetically regulated. Dysregulation of rRNA synthesis and ribosome biogenesis are characteristic features of cancers. Targeting aberrant rRNA expression for cancer therapy is being explored. Head and neck squamous cell carcinoma (HNSCC) is among the most prevalent cancers globally. Using quantitative PCR and bisulfite sequencing, we show that rRNA genes are...
Source: Gene - September 11, 2023 Category: Genetics & Stem Cells Authors: Neha Priyadarshini Navinchandra Venkatarama Puppala Jayasree Peroth Jayaprakash Piyush Khandelia Vivek Sharma Gireesha Mohannath Source Type: research
Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression
CONCLUSION: In conclusion, in vitro and in silico investigations show that the RMV extract improves the anticancer efficiency of SOR through molecular processes involving the downregulation of mTOR, BCl2, and JNK1 and overexpression of p21 tumor suppressor gene. Finally, we suggest conducting additional in vivo investigations on RMV and its bioactive components to verify their potential in cancer therapy.PMID:37696244 | DOI:10.1016/j.prp.2023.154807
Source: Pathology, Research and Practice - September 11, 2023 Category: Pathology Authors: Aml Ghanem Mohamed A Ali Mohamed A Elkady Sherif S Abdel Mageed Mahmoud A El Hassab Mohamed K El-Ashrey Osama A Mohammed Ahmed S Doghish Source Type: research
Ribosomal RNA gene downregulation in head and neck squamous carcinoma cells correlates with rDNA promoter hypermethylation
Gene. 2023 Sep 9:147793. doi: 10.1016/j.gene.2023.147793. Online ahead of print.ABSTRACTEukaryotes carry hundreds of ribosomal RNA (rRNA) genes as tandem arrays, which generate rRNA for protein synthesis. Humans carry ∼ 400 rRNA gene copies and their expression is epigenetically regulated. Dysregulation of rRNA synthesis and ribosome biogenesis are characteristic features of cancers. Targeting aberrant rRNA expression for cancer therapy is being explored. Head and neck squamous cell carcinoma (HNSCC) is among the most prevalent cancers globally. Using quantitative PCR and bisulfite sequencing, we show that rRNA genes are...
Source: Gene - September 11, 2023 Category: Genetics & Stem Cells Authors: Neha Priyadarshini Navinchandra Venkatarama Puppala Jayasree Peroth Jayaprakash Piyush Khandelia Vivek Sharma Gireesha Mohannath Source Type: research
Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression
CONCLUSION: In conclusion, in vitro and in silico investigations show that the RMV extract improves the anticancer efficiency of SOR through molecular processes involving the downregulation of mTOR, BCl2, and JNK1 and overexpression of p21 tumor suppressor gene. Finally, we suggest conducting additional in vivo investigations on RMV and its bioactive components to verify their potential in cancer therapy.PMID:37696244 | DOI:10.1016/j.prp.2023.154807
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Aml Ghanem Mohamed A Ali Mohamed A Elkady Sherif S Abdel Mageed Mahmoud A El Hassab Mohamed K El-Ashrey Osama A Mohammed Ahmed S Doghish Source Type: research
slan+ monocytes kill cancer cells coated in therapeutic antibody by trogoptosis
Cancer Immunol Res. 2023 Sep 11. doi: 10.1158/2326-6066.CIR-23-0239. Online ahead of print.ABSTRACTMonocytes positive for 6-Sulfo LacNAc (slan) are a major subset of non-classical CD14dimCD16+ monocytes in humans. We have shown that slan+ cells infiltrate lymphomas and elicit an antibody-dependent cellular cytotoxicity (ADCC) of neoplastic B cells mediated by the anti-CD20 therapeutic Rituximab. Herein, by performing blocking experiments and flow cytometry analyses, as well as confocal microscopy and live-cell imaging assays, we extended the findings to other humanized antibodies and deciphered the underlying effector mech...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Giulia Finotti Enrica Pietronigro Camillo Balanzin Silvia Lonardi Gabriela Constantin Mark P Chao Cristina Tecchio William Vermi Marco A Cassatella Source Type: research
Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report
Explor Res Clin Soc Pharm. 2023 Aug 24;11:100324. doi: 10.1016/j.rcsop.2023.100324. eCollection 2023 Sep.ABSTRACTThis case report describes the pharmacist intervention with a 62-year-old woman who had postmenopausal breast cancer. The patient was experiencing severe vasomotor symptoms from her cancer therapy and wanted to discontinue her treatment despite her risk of cancer returning. Using guidelines for treatment of postmenopausal breast cancer and medication options to mitigate vasomotor symptoms, the pharmacist developed a treatment plan that was acceptable to the patient and approved by the oncologist. Following imple...
Source: Clinical Genitourinary Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Megan R Undeberg Alanda Barash Kimberly C McKeirnan Source Type: research
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research
